A Phase Ib/II trial of SB 11285 in liver cancer

Trial Profile

A Phase Ib/II trial of SB 11285 in liver cancer

Phase of Trial: Phase I/II

Latest Information Update: 07 Nov 2017

At a glance

  • Drugs SB 11285 (Primary)
  • Indications Liver cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 07 Nov 2017 New trial record
    • 31 Oct 2017 According to a Spring Bank Pharmaceuticals media release, the company is planning to submit an IND, and/or a CTA in mid-2018 to start this trial in the second half of 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top